Breaking News Instant updates and real-time market news.

CELG

Celgene

$84.83

1.23 (1.47%)

, NVS

Novartis

$78.82

1.67 (2.16%)

10:23
07/12/18
07/12
10:23
07/12/18
10:23

PTAB decision on Gilenya positive for Celgene, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond expects the market to react positively with respect to Celgene (CELG) shares, at least initially, following the Patent Trial and Appeal Board decision regarding ozanimod competitor Gilenya from Novartis (NVS). Yesterday, the PTAB issued a decision that upholds validity of Gilenya's dosing patent in response to inter partes review petitions from multiple generic filers, Raymond tells investors in a research note. While this decision will likely be appealed, it opens up the possibility for Gilenya intellectual property runway out to 2027, when the dosing patent expire, the analyst adds. Raymond believes that not having a generic S1P class at launch for ozanimod is positive for Celgene. However, without the removal of first dose monitoring, ozanimod is not likely to be differentiated enough to make a difference, the analyst says, citing physician feedback. He keeps a Neutral rating on Celgene with a $95 price target. The stock in early trading is up 2% to $84.92.

CELG

Celgene

$84.83

1.23 (1.47%)

NVS

Novartis

$78.82

1.67 (2.16%)

  • 26

    Jul

CELG Celgene
$84.83

1.23 (1.47%)

07/10/18
PIPR
07/10/18
DOWNGRADE
Target $52
PIPR
Neutral
Acceleron downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff downgraded Acceleron Pharma (XLRN) to Neutral and lowered his price target for the shares to $52 from $55. Acceleron and partner Celgene (CELG) last night announced positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia, Tenthoff tells investors in a research note. The stock in premarket trading is up $6.10, or 13%, to $53.50. This is a nice second win for luspatercept, but Acceleron shares are not a buy at current valuation levels, the analyst contends. He believes luspatercept does not command the same market opportunity in beta thalassemia due to the expected approval of curative gene therapy by 2020. As such, Tenthoff lowered his penetration rates for luspatercept in beta thal to account for gene therapy competition. He says, however, that partner Celgene could acquire Acceleron, which presents a risk to his downgrade.
07/10/18
PIPR
07/10/18
NO CHANGE
PIPR
Neutral
Celgene raised prices on both Revlimid and Pomalyst by 5%, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that Wolters Kluwer Health reports that Celgene increased its prices for Revlimid and Pomalyst by 5%, effective yesterday. The analyst, who pointed out that this is the first increase since October 2017 for both drugs, said the price hikes should provide some tailwind to Celgene's second half results. He maintains his Neutral rating on Celgene shares.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
NVS Novartis
$78.82

1.67 (2.16%)

07/02/18
RILY
07/02/18
NO CHANGE
Target $7.5
RILY
Buy
Adamis price target raised to $7.50 from $6.25 at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva raised his price target for Adamis Pharmaceuticals (ADMP) to $7.50 after the company entered into a strategic partnership with Novartis (NVS) unit Sandoz. The analyst views the agreement as favorable and keeps a Buy rating on Adamis.
07/02/18
HCWC
07/02/18
NO CHANGE
Target $10
HCWC
Buy
Adamis price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert raised his price target for Adamis Pharmaceuticals (ADMP) to $10 after the company announced that Novartis (NVS) division Sandoz division will commercialize Symjepi. While the deal took longer than expected, the terms of a 50:50 split is better than anticipated, Kolbert tells investors in a research note. The analyst sees Sandoz as a "great partner" and reiterates a Buy rating on Adamis.
07/02/18
ROTH
07/02/18
NO CHANGE
Target $22
ROTH
Buy
Cryoport price target raised to $22 from $12.50 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for Cryoport (CYRX) to $22 from $12.50 while reiterating a Buy rating on the shares. The analyst notes that the European Medicines Agency recommended "marketing authorizations" for therapies developed by two of Cryoport's clients, Gilead's (GILD) Yescarta and Novartis' (NVS) Kymriah. Baldry believes these two approvals roughly double the addressable market for the therapies and offer upside potential to our 2019 forecasts.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

GSK

GlaxoSmithKline

$40.84

0.145 (0.36%)

14:36
07/20/18
07/20
14:36
07/20/18
14:36
Periodicals
Breaking Periodicals news story on GlaxoSmithKline »

GSK board discussing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

14:30
07/20/18
07/20
14:30
07/20/18
14:30
General news
More dollar index slippage and yield rises »

More dollar index…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

14:24
07/20/18
07/20
14:24
07/20/18
14:24
Hot Stocks
Sen. Schumer: Trump's backtrack on ZTE example of 'being weak' »

Top Senate Democrat Chuck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

ZTCOY

ZTE Corp.

$0.00

(0.00%)

14:21
07/20/18
07/20
14:21
07/20/18
14:21
Periodicals
Lawmakers remove anti-ZTE measure from defense bill, Reuters says »

Top Senate Democrat Chuck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/20/18
07/20
14:17
07/20/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/20/18
07/20
14:16
07/20/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RS

Reliance Steel

$91.30

0.24 (0.26%)

14:10
07/20/18
07/20
14:10
07/20/18
14:10
Options
Call buyers in Reliant Steel ahead of earnings next week »

Call buyers in Reliant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.04

0.09 (0.03%)

14:08
07/20/18
07/20
14:08
07/20/18
14:08
General news
Trump worried Fed will hike rates twice this year, CNBC reports 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.04

0.09 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
07/20/18
07/20
14:05
07/20/18
14:05
General news
Action Economics Survey results: »

Action Economics Survey…

SWN

Southwestern Energy

$5.36

-0.005 (-0.09%)

13:55
07/20/18
07/20
13:55
07/20/18
13:55
Options
Southwestern Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

13:55
07/20/18
07/20
13:55
07/20/18
13:55
General news
Treasury Curve Action: longer yields led to steepening »

Treasury Curve Action:…

LHO

LaSalle Hotel

$35.10

0.11 (0.31%)

, PEB

Pebblebrook Hotel

$39.66

-0.06 (-0.15%)

13:47
07/20/18
07/20
13:47
07/20/18
13:47
Hot Stocks
LaSalle Hotel confirms receipt of letter from Pebblebrook Hotel »

LaSalle Hotel Properties…

LHO

LaSalle Hotel

$35.10

0.11 (0.31%)

PEB

Pebblebrook Hotel

$39.66

-0.06 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ARDX

Ardelyx

$4.40

-0.05 (-1.12%)

13:42
07/20/18
07/20
13:42
07/20/18
13:42
Hot Stocks
Breaking Hot Stocks news story on Ardelyx »

Adage Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$55.30

-4.1 (-6.90%)

13:42
07/20/18
07/20
13:42
07/20/18
13:42
Recommendations
Lumentum analyst commentary  »

Lumentum should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$64.01

-0.49 (-0.76%)

13:40
07/20/18
07/20
13:40
07/20/18
13:40
Options
Hess sees aggressive call buying ahead of earnings next week »

Hess sees aggressive call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

FFIV

F5 Networks

$172.71

1.06 (0.62%)

, S

Sprint

$5.46

-0.015 (-0.27%)

13:39
07/20/18
07/20
13:39
07/20/18
13:39
Hot Stocks
F5 Networks names Sprint CEO Michel Combes to board »

F5 Networks (FFIV)…

FFIV

F5 Networks

$172.71

1.06 (0.62%)

S

Sprint

$5.46

-0.015 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

  • 08

    Aug

  • 09

    Aug

LGF.A

Lionsgate

$24.92

-0.04 (-0.16%)

, LGF.B

Lionsgate

$23.91

-0.06 (-0.25%)

13:37
07/20/18
07/20
13:37
07/20/18
13:37
Periodicals
Ex-Lions Gate general counsel was mired in legal drama prior to exit, WSJ says »

Lions Gate general…

LGF.A

Lionsgate

$24.92

-0.04 (-0.16%)

LGF.B

Lionsgate

$23.91

-0.06 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

UNIT

Uniti Group

$17.85

-0.785 (-4.21%)

13:35
07/20/18
07/20
13:35
07/20/18
13:35
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

LITE

Lumentum

$55.30

-4.1 (-6.90%)

13:33
07/20/18
07/20
13:33
07/20/18
13:33
Recommendations
Lumentum analyst commentary  »

Lumentum selloff today a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$280.19

0.24 (0.09%)

, IWM

iShares Trust Russell 2000 Index Fund

$169.13

-0.01 (-0.01%)

13:30
07/20/18
07/20
13:30
07/20/18
13:30
Technical Analysis
On The Fly: ETF fund flow highlights »

For the past week, there…

SPY

SPDR S&P 500 ETF Trust

$280.19

0.24 (0.09%)

IWM

iShares Trust Russell 2000 Index Fund

$169.13

-0.01 (-0.01%)

QQQ

Invesco QQQ Trust

$179.51

0.48 (0.27%)

BBJP

JPMorgan BetaBuilders Japan ETF

$24.08

0.065 (0.27%)

XLF

Financial Select Sector

$27.59

0.085 (0.31%)

XLI

Industrial Select Sector SPDR

$74.65

0.12 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$194.73

2.71 (1.41%)

13:24
07/20/18
07/20
13:24
07/20/18
13:24
Hot Stocks
Canadian Pacific, TCRC-T&E ratify four-year agreement »

Canadian Pacific Railway…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,821.64

8.79 (0.48%)

13:17
07/20/18
07/20
13:17
07/20/18
13:17
Hot Stocks
Amazon announces new fulfillment center in Spokane »

Amazon.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/20/18
07/20
13:17
07/20/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/20/18
07/20
13:16
07/20/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESL

Esterline

$81.10

5.6 (7.42%)

13:11
07/20/18
07/20
13:11
07/20/18
13:11
Periodicals
Esterline in early stages of exploring sale, WSJ reports »

Esterline Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.